Ran Cui

Dr. Ran Cui


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Medicine
Verified
Journal Article
Open access
NYNianxun Yi
Nianxun Yi
ZWZhangling Wang
Zhangling Wang
RCRan Cui
Ran Cui
Background: This study investigated the application of a composite warming strategy in the perioperative care of patients who underwent open hepatectomy for liver cancer. The clinical efficacy of the composite warming strategy was observed and analyzed, and the factors causing hypothermia were discussed. Methods: From January 2020 to December 2021, 80 patients were selected for the study. The control group adopted perioperative forced-air warming measures, while the experimental group implemented a composite warming strategy. The clinical data of the 2 groups of patients were compared, and the factors influencing intraoperative hypothermia were explored. Results: The incidence of hypothermia in the composite warming strategy group was significantly lower than that in the forced-air warming group (P = .015). There were no significant differences in sex, age, BMI, stage of liver cancer, presence of liver cirrhosis, chronic hepatitis, history of alcohol consumption, PLT, PT, pain score, length of hospital stay, etc, between the 2 groups (P > .05). However, there were significant differences in intraoperative fluid volume, anesthesia time, intraoperative blood loss, and PACU observation time (P < .05). Multivariate analysis revealed that intraoperative blood loss, intraoperative fluid replacement volume, and operation time were factors influencing intraoperative hypothermia (P < .05). Conclusion: The composite warming strategy plays a role in preventing hypothermia during open hepatectomy for liver cancer. The occurrence of hypothermia during open hepatectomy for liver cancer patients is related to intraoperative blood loss, intraoperative fluid replacement volume, and anesthesia time.

4 July 2025 in Medicine
Verified
Journal Article
Open access
LYLi Yu
Li Yu
XCXiao Chen
Xiao Chen
XWXiulan Wang
Xiulan Wang
RCRan Cui
Ran Cui
Pulmonary hypertension (PH) patients with acute respiratory failure (ARF) face high morbidity and mortality rates. This study aimed to determine the optimal respiratory support strategy (high-flow nasal cannula [HFNC] vs noninvasive ventilation) across different grades of RV dysfunction severity in these patients. In this retrospective cohort study, we stratified 90 PH patients with ARF into mild, moderate or severe right ventricular (RV) dysfunction subgroups via propensity score matching. We compared 28-day mortality rates and intubation rates as primary outcomes between the HFNC and noninvasive ventilation (NIV) groups. There were no differences in 28-day mortality between HFNC therapy and NIV among the RV dysfunction subgroups. In patients with severe RV dysfunction, however, HFNC therapy was associated with significantly greater intubation rates. Both therapies improved right heart function, but NIV yielded better oxygenation. HFNC therapy is as effective as NIV in mild to moderate RV dysfunction; nevertheless, NIV might be more advantageous for severe cases. These findings can help in choosing between HFNC therapy and NIV for PH patients who present with ARF. Nonetheless, larger prospective trials are needed to validate these findings.

22 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
YLYulin Lei
Yulin Lei
WYWenli Yang
Wenli Yang
WZWen Zhong
Wen Zhong
RCRan Cui
Ran Cui
Background/Objectives: Distal cholangiocarcinoma is a rare biliary tract cancer typically treated with pancreaticoduodenectomy. Comparative evidence specifically addressing minimally invasive versus open pancreaticoduodenectomy for this disease remains scarce. Methods: We conducted an updated systematic review and pairwise meta-analysis of comparative studies limited to distal cholangiocarcinoma. Binary outcomes were summarized as odds ratios, continuous outcomes as mean differences, and overall survival as hazard ratios. The primary survival analysis included only directly reported hazard ratios from prespecified matched or weighted cohorts; hazard ratios reconstructed from Kaplan–Meier curves were examined only in sensitivity analyses. Results: Six retrospective comparative studies involving 1623 patients met the inclusion criteria. Minimally invasive surgery was associated with lower blood loss (mean difference, −104.93 mL; 95% CI, −145.30 to −64.57; I2 = 16.3%). No clear differences were found in clinically relevant postoperative pancreatic fistula (odds ratio, 1.03; 95% CI, 0.85 to 1.25), major morbidity (odds ratio, 0.96; 95% CI, 0.64 to 1.43), or R0 resection (odds ratio, 1.22; 95% CI, 0.96 to 1.56). In the primary overall survival analysis based on directly reported hazard ratios, the pooled hazard ratio was 0.93 (95% CI, 0.57 to 1.52; I2 = 1.3%). In the sensitivity analysis incorporating eligible reconstructed hazard ratios, the pooled hazard ratio was 0.88 (95% CI, 0.73 to 1.05). In an exploratory recurrence-related survival family analysis based on directly reported estimates, the pooled hazard ratio was 0.95 (95% CI, 0.83 to 1.07; I2 = 0.0%). Conclusions: Minimally invasive pancreaticoduodenectomy may reduce blood loss without clear evidence of worse major postoperative or oncologic outcomes in distal cholangiocarcinoma. However, the available evidence is entirely observational and should be interpreted with caution.

10 December 2025 in International Journal of Surgery
Verified
Journal Article
Open access
XYXinlin Yu
Xinlin Yu
XZXialin Zhang
Xialin Zhang
OJOu Jiang
Ou Jiang
XLXinwei Li
Xinwei Li
GCGang Chen
Gang Chen
RCRan Cui
Ran Cui
Background: Advanced hepatocellular carcinoma (HCC) is aggressive with high mortality. Optimizing immune checkpoint inhibitor (ICI)-based regimens is critical, yet comparative efficacy and safety of ICI combinations remain unclear, limiting personalized treatment. Objective: To compare efficacy and safety of ICI-based combination therapies for advanced HCC via systematic review and network meta-analysis (NMA). Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science from January 2000 to May 2025 for studies evaluating ICI-containing regimens in patients with advanced HCC. Objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) are primary indicators of efficacy, whereas treatment-related adverse events (trAEs) are the primary safety indicator. Results: Across 41 studies (n=16 008), toripalimab-based combination showed the longest survival [mPFS: 9.6 months (95% CI 8.3–11.0); mOS: 17.1 months (95% CI 14.0–20.0)], and the ICI + hepatic artery infusion chemotherapy + tyrosine kinase inhibitor combination showed a comparatively high efficacy profile [mPFS: 10.8 months (95% CI 9.6–11.6); mOS: 21.1 months (95% CI 15.0–27.2)]. Atezolizumab-based combination had the lowest severe trAEs (SUCRA = 26.8%), and immunotherapy as initial treatment markedly reduced toxicity versus other sequencing strategies (SUCRA = 12.9% vs. 46.4% for grade 3–4 trAEs). Programmed cell death protein 1 (PD-1) inhibitors showed greater efficacy but slightly greater toxicity than programmed cell death-ligand 1 (PD-L1) inhibitors (ORR SUCRA = 99.1% vs. 49.7%; grade 3–4 trAEs: 44.5% vs. 43.6%). Conclusions: This systematic review and NMA reveals substantial heterogeneity in efficacy and safety profiles among ICIs-based combinations for advanced HCC. These findings support individualized treatment selection matching patient profiles with regimen-specific risk-benefit patterns, with toxicity monitoring to optimize outcomes.

20 November 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LYLi Yu
Li Yu
XYXinlin Yu
Xinlin Yu
CMCheng Ma
Cheng Ma
XZXialin Zhang
Xialin Zhang
RCRan Cui
Ran Cui
Background: Limited-stage small cell lung cancer (LS-SCLC) has a poor prognosis despite being potentially curable with standard concurrent chemoradiotherapy. The success of immune checkpoint inhibitors (ICIs) in extensive-stage SCLC has prompted investigation into combining immunotherapy with radiotherapy for LS-SCLC. This systematic review and single-arm meta-analysis aims to synthesize the evidence on this combined modality, providing pooled estimates of efficacy and safety to inform clinical practice and future trials. Methods: Following PRISMA guidelines, we systematically searched PubMed, Embase, Cochrane Library, and Web of Science through July 2025 for studies evaluating radiotherapy combined with immunotherapy in patients with LS-SCLC. The primary outcomes analyzed included pooled objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS). Results: Six studies, encompassing 487 patients, met the inclusion criteria. The pooled analysis demonstrated an ORR of 57.7% (95% CI: 24.9–90.5%), a weighted mPFS of 13.6 months (95% CI: 11.3–15.9 months), and a pooled mOS of 33.7 months (95% CI: 26.7–40.7 months). Grade 3−4 treatment-related adverse events occurred in 42.2% of patients. Subgroup analyses revealed that a concurrent treatment sequence yielded a significantly higher ORR compared to sequential approaches (77.6% vs. 65.2% for immunotherapy followed by radiation vs. 25.8% for radiation followed by immunotherapy). Radiation dose was also identified as a critical determinant of efficacy. Anti-PD-L1 agents showed a numerically higher ORR than anti-PD-1 agents (96.0% vs. 65.0%). Conclusion: The combination of radiotherapy and immunotherapy is a promising therapeutic strategy for LS-SCLC, demonstrating encouraging efficacy outcomes that appear favorable compared to historical benchmarks for chemoradiotherapy alone. Optimizing treatment sequencing, particularly favoring a concurrent approach, is crucial for maximizing clinical benefit. These findings support further investigation in randomized controlled trials to confirm the value of this combined modality and to identify predictive biomarkers for patient selection.

20 September 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
SJShu Jiang
Shu Jiang
YLYan Liu
Yan Liu
RCRan Cui
Ran Cui
Background/Objectives: Adults eligible for respiratory syncytial virus (RSV) vaccination may also receive influenza, COVID-19, pneumococcal, or herpes zoster vaccines. We compared immunogenicity and safety between coadministration and sequential schedules. Methods: We searched PubMed, Embase, Web of Science, Scopus, and CENTRAL from inception to 3 August 2026 for randomized trials in adults aged 50 years or older. Eligible trials compared RSVPreF3 OA coadministration with sequential administration of the partner vaccine followed by RSVPreF3 OA. Random-effects models pooled neutralizing-antibody geometric mean ratios (GMRs; coadministration/sequential) separately for RSV-A and RSV-B and risk ratios for safety outcomes. Risk of bias and certainty were assessed using RoB 2 and GRADE, respectively. Results: Six trials randomized 5455 participants. Pooled RSV-A and RSV-B GMRs were 0.895 (95% CI 0.816–0.983) and 0.922 (95% CI 0.837–1.016), respectively. In trial-specific per-protocol analyses, non-inferiority criteria were met for recombinant zoster vaccine (RZV) and 20-valent pneumococcal conjugate vaccine (PCV20) antibody endpoints, but non-inferiority was not demonstrated for SARS-CoV-2 XBB.1.5 neutralizing antibodies (GMR 0.763, 95% CI 0.662–0.885) or the adjuvanted quadrivalent influenza vaccine A/H3N2 response. The pooled risk ratio for serious adverse events was 0.831 (95% CI 0.530–1.303), with limited precision. Certainty was low for RSV-A and very low for RSV-B, mainly reflecting risk of bias and inconsistency. Conclusions: In adults aged 50 years or older, same-day RSVPreF3 OA coadministration was associated with lower RSV-neutralizing antibody responses than sequential administration, while partner-vaccine immunogenicity varied by product and antigen. Non-inferiority was not demonstrated for the SARS-CoV-2 XBB.1.5 and adjuvanted-QIV A/H3N2 antibody endpoints. No clear safety difference between schedules was identified, and the clinical significance of the antibody differences remains uncertain. Registration: PROSPERO CRD420261470812.